A randomized trial of treatment for multisystem Langerhans' cell histiocytosis

Journal of Pediatrics

Volumn 138, Issue 5, 2001, Pages 728-734

  Gadner, Helmut ^{a,b,c,d,e,f,g,h,i,j}   Grois, Nicole ^{a,b,c,d,e,f,g,h,i,j}   Arico, Maurizio ^{a,b,c,d,e,f,g,h,i,j}   Broadbent, Valerie ^{a,b,c,d,e,f,g,h,i,j}   Ceci, Adriana ^{a,b,c,d,e,f,g,h,i,j}   Jakobson, Ake ^{a,b,c,d,e,f,g,h,i,j}   Komp, Diane ^{a,b,c,d,e,f,g,h,i,j}   Michaelis, Jörg ^{a,b,c,d,e,f,g,h,i,j}   Nicholson, Stacy ^{a,b,c,d,e,f,g,h,i,j}   Pötschger, Ulrike ^{a,b,c,d,e,f,g,h,i,j}   Pritchard, Jon ^{a,b,c,d,e,f,g,h,i,j}   Ladisch, Stephan ^{a,b,c,d,e,f,g,h,i,j}  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b UNIVERSITY OF PAVIA   (Italy)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BARI   (Italy)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g JOHANNES GUTENBERG UNIVERSITY   (Germany)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j CHILDREN S RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; METHYLPREDNISOLONE; VINBLASTINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES INSIPIDUS; DRUG EFFICACY; FEMALE; HISTIOCYTOSIS X; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SURVIVAL; TREATMENT OUTCOME;

EID: 0035018142     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1067/mpd.2001.111331     Document Type: Article

References (25)

1. Nosology and pathology of Langerhans cell histiocytosis
2. Langerhans' cell histiocytosis (histiocytosis X) - A clonal proliferative disease
3. Langerhans cell histiocytosis
4. Langerhans cell histiocytosis: Diagnosis, natural history, management, and outcome
5. The histiocytoses
6. Histiocytosis X - An analysis of prognostic factors
7. A staging system for histiocytosis X: A southwest oncology group study
8. Treatment strategy for disseminated Langerhans cell histiocytosis
9. Langerhans cell histiocytosis: The case for conservative treatment
10. Treatment of LCH- evolution and current approaches
11. Etoposide (VP16) in the treatment of multisystem Langerhans cell histiocytosis (histiocytosis X)
12. Etoposide in recurrent childhood Langerhans cell histiocytosis: An Italian cooperative study
13. Response to therapy in multisystem Langerhans cell histiocytosis (LCH). Results from the DAL HX-83 and DAL HX-90 studies
14. Histiocytosis syndromes in children
15. Histiocytosis syndromes in children II Approach to the clinical and laboratory evaluation of children with Langerhans cell histiocytosis
16. LCH-I: A randomized trial of etoposide versus vinblastine in disseminated Langerhans cell histiocytosis
17. Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer
18. Langerhans cell histiocytosis and etoposide: Risk vs benefits
19. Statistical principles for clinical trials. ICH harmonised tripartite guideline
20. Central nervous system disease in Langerhans cell histiocytosis
21. Diabetes insipidus associated with Langerhans cell histiocytosis: Is it reversible?
22. VP-16 and the treatment of histiocytosis
23. Increased risk of secondary leukemia after single-agent treatment with etoposide for Langerhans cell histiocytosis
24. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90